TY - JOUR
T1 - Pulmonary and lymph node metastases of renal cell carcinoma which completely responded to oral administration of UFT--a case report
AU - Hoshi, Kiyotsugu
AU - Kanbara, Taiki
AU - Kawasaki, Yoshihide
AU - Ikeda, Yoshihiro
AU - Namima, Takashige
AU - Ohnuma, Tetsutaro
PY - 2007/8
Y1 - 2007/8
N2 - In April 2003, a 59-year-old woman suffering from renal cell carcinoma (RCC) underwent radical nephrectomy (Stage I). In October 2004, bilateral lower lobe lung tumors were resected with thoracoscopic assistance. Histologically, resected specimens were diagnosed as metastases from RCC. However, 2 months later,lung and abdominal lymph node metastases were detected by CT. Chemotherapy with interferon-alpha (IFN-alpha) 6,000,000 units every day was performed, but was discontinued after 3 months due to fatigue and depression. Because the tumor marker (IAP) level and the size of the metastatic tumors increased, second-line chemotherapy with oral administration of tegafur/uracil (UFT-E 600 mg/day) was started. Six months after UFT administration, there was a significant decrease of tumor markers and the metastatic tumors were disappeared, therefore we were judged as complete response (CR). No grade 3 or more severs adverse reactions have been observed. Some cases may be effectively treated by UFT after treatment failure of IFN-alpha therapy. This UFT therapy is simple and possible to continue safely on an outpatient chemotherapy while maintaining quality of life.
AB - In April 2003, a 59-year-old woman suffering from renal cell carcinoma (RCC) underwent radical nephrectomy (Stage I). In October 2004, bilateral lower lobe lung tumors were resected with thoracoscopic assistance. Histologically, resected specimens were diagnosed as metastases from RCC. However, 2 months later,lung and abdominal lymph node metastases were detected by CT. Chemotherapy with interferon-alpha (IFN-alpha) 6,000,000 units every day was performed, but was discontinued after 3 months due to fatigue and depression. Because the tumor marker (IAP) level and the size of the metastatic tumors increased, second-line chemotherapy with oral administration of tegafur/uracil (UFT-E 600 mg/day) was started. Six months after UFT administration, there was a significant decrease of tumor markers and the metastatic tumors were disappeared, therefore we were judged as complete response (CR). No grade 3 or more severs adverse reactions have been observed. Some cases may be effectively treated by UFT after treatment failure of IFN-alpha therapy. This UFT therapy is simple and possible to continue safely on an outpatient chemotherapy while maintaining quality of life.
UR - http://www.scopus.com/inward/record.url?scp=34548842258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548842258&partnerID=8YFLogxK
M3 - Article
C2 - 17687222
AN - SCOPUS:34548842258
SN - 0385-0684
VL - 34
SP - 1315
EP - 1317
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 8
ER -